View Clinical Trial (Medical Research Study)
A Case Control Study to Evaluate Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis.
| City: |
|
Washington |
| State: |
|
District of Columbia |
| Zip Code: |
|
20037 |
| Conditions: |
|
Psoriasis - Cardiovascular Diseases - Dyslipidemia |
| Purpose: |
|
Psoriasis patients are known to be at increased risk for heart disease. This may be due to
the increased prevalence of cardiovascular disease risk factors in this population,
including high blood pressure, diabetes, obesity, and high cholesterol. Although
cholesterol levels are known to be altered in psoriasis, most studies have used standard
lipid profiles to measure cholesterol. These tests indirectly measure LDL (bad cholesterol)
and become less accurate when triglyceride levels are high, as often see in individuals with
psoriasis. We have designed a case-control study that uses a more specific and detailed
cholesterol test to measure serum lipid levels in psoriasis patients, allowing for more
accurate determination of LDL and better assessment of the lipid-contribution to
cardiovascular risk. We will also measure other markers of inflammation that may contribute
to cardiovascular disease.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Adults of both sexes from our dermatology clinic, between the age 18 and 80 years who
wish to participate voluntarily in the study and who have signed a written informed
consent form to participate. Cases will have a diagnosis of psoriasis as diagnosed
by our principal investigator, while controls will be selected from the same
dermatology clinic.
Exclusion Criteria:
- Current or past use (within 6-8 weeks) of anti-hyperlipidemic agents (statins,
fibrates, neomycin, niacin, ezetimibe) and/or any other medications significantly
affecting lipid metabolism, including cyclosporine, acitretin, protease inhibitors,
tamoxifen, clozapine, and estrogen replacement therapy.
- Presence of secondary causes of hyperlipidemia including diabetes mellitus, smoking,
untreated hypothyroidism, nephrotic syndrome, chronic kidney disease, and cholestatic
liver disease (e.g. primary biliary cirrhosis).
- History of cardiovascular disease (e.g. previous myocardial infarction, stroke, or
angioplasty performed secondary to atherosclerosis).
- History of alcohol intake >30 g/day in males and >20 g/day in females.
- Pregnancy
- Subjects with conditions or diseases hindering data collection and follow up, such as
incapacitating diseases, cognitive deterioration, institutionalized patients.
|
| NCT ID: |
|
NCT01019200 |
| Primary Contact: |
|
Principal Investigator
Alison Ehrlich, MD
GWU
Amir Zahir, MD
Phone: 202-741-2632
Email: azahir@mfa.gwu.edu
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Washington, District of Columbia 20037
United States
Alison Ehrlich, MD
Phone: 202-741-2600
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 18, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|